Sub section - Healthtech
Foundation Medicine, Inc., a precision medicine leader transforming cancer care, has announced a strategic partnership with Manifold, a leading artificial intelligence (AI) data platform for life sciences. This collaboration brings advanced AI capabilities to FoundationInsights®, the company’s cloud-based data analytics and visualization platform designed to generate insights from its extensive multimodal datasets.
The upgraded version of FoundationInsights® is now available to biopharmaceutical partners, offering greater flexibility and speed in exploring genomic data to support drug development. Powered by Manifold’s AI data platform, the enhanced system enables a more intuitive and efficient way to extract insights from Foundation Medicine’s proprietary database — comprising de-identified genomic results from over 800,000 patients.
Through FoundationInsights®, users can quickly identify patient cohorts or assess the prevalence of specific genomic alterations. The platform’s AI-enabled natural language interface allows researchers to easily set complex genomic criteria through simple queries. For more advanced exploration, technical users can perform customized analyses using programming languages such as Python and R.
“Foundation Medicine is using AI and machine learning to power our real-world data solutions to accelerate drug discovery and development. With new AI-powered capabilities from Manifold, biopharmaceutical partners can find the answers needed to make decisions faster than ever before,” said Troy Schurr, Chief Biopharma Business Officer at Foundation Medicine. “Our partners now have a one-stop shop to easily access comprehensive multimodal data from Foundation Medicine combined with advanced analytics and visualization tools, so patients can benefit from advances in precision medicine.”
Vinay Seth Mohta, CEO and co-founder of Manifold, added, “Foundation Medicine is a pioneer in precision diagnostics. By combining Foundation Medicine’s powerful multimodal databases with Manifold’s purpose-built AI capabilities for life sciences, together we can make it easier for researchers to work smarter and faster to unlock the answers needed to discover innovative personalized therapies.”
The AI-enhanced FoundationInsights® powered by Manifold is currently available to biopharmaceutical partners, with a customized version for healthcare providers and health systems planned for launch in 2026.